Cholesteryl ester transfer protein and its inhibition.

Cell Mol Life Sci

Bayer Healthcare AG/Bayer Schering Pharma, 42096, Wuppertal, Germany.

Published: September 2010

Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of cholesteryl esters from the atheroprotective high density lipoprotein (HDL) to the proatherogenic low density lipoprotein cholesterol (LDL) and very low density lipoprotein cholesterol (VLDL) leading to lower levels of HDL but raising the levels of proatherogenic LDL and VLDL. Inhibition of CETP is considered a potential approach to treat dyslipidemia. However, discussions regarding the role of CETP-mediated lipid transfer in the development of atherosclerosis and CETP inhibition as a potential strategy for prevention of atherosclerosis have been controversial. Although many animal studies support the hypothesis that inhibition of CETP activity may be beneficial, negative phase III studies on clinical endpoints with the CETP inhibitor torcetrapib challenged the future perspectives of CETP inhibitors as potential therapeutic agents. The review provides an update on current understanding of the molecular mechanisms involved in CETP activity and its inhibition.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11115880PMC
http://dx.doi.org/10.1007/s00018-010-0418-3DOI Listing

Publication Analysis

Top Keywords

density lipoprotein
12
cholesteryl ester
8
ester transfer
8
transfer protein
8
low density
8
lipoprotein cholesterol
8
inhibition cetp
8
cetp activity
8
cetp
7
inhibition
5

Similar Publications

Homozygous Familial Hypercholesterolemia Treatment: New Developments.

Curr Atheroscler Rep

January 2025

Carbohydrate and Lipid Metabolism Research Unit, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa.

Purpose Of Review: Homozygous familial hypercholesterolaemia (HoFH) is characterized by marked elevation of low-density lipoprotein cholesterol (LDLC) and premature atherosclerotic cardiovascular disease. This is a review of novel pharmacological therapies to lower LDLC in patients with HoFH.

Recent Findings: Novel therapies can be broadly divided by whether their efficacy is dependent or independent of residual low-density lipoprotein receptor (LDLR) function.

View Article and Find Full Text PDF

Objective: Kawasaki disease (KD) is a common children's disease with unknown etiology, which easily involves coronary artery and causes serious cardiovascular sequelae. The purpose was to investigate the relationship between chitotriosidase activity and coronary artery aneurysm (CAA) and develop and validate a nomogram to predict CAA in KD patients.

Methods: A total of 338 KD patients were included in this study.

View Article and Find Full Text PDF

Background: Peripheral metabolic health status can reflect and/or contribute to the risk of Alzheimer's disease (AD). Peripheral metabolic health status can be indicated by metabolic health markers, such as inflammatory biomarker glycoprotein acetyls (GlycA) and specific components of lipoproteins (e.g.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Huashan Hospital, Fudan University, Shanghai, China.

Background: Identifying circulating metabolites associated with dementia, cognition, and brain volume may improve the understanding of dementia pathogenesis and provide novel insights for preventive and therapeutic interventions.

Method: This cohort study included a total of 87,885 participants (median follow-up 9.1 years, 54% female) without dementia at baseline from the UK Biobank.

View Article and Find Full Text PDF

Introduction: This report presents prevalence of high total cholesterol and low high-density lipoprotein cholesterol (HDL-C) by sex and age group for adults age 20 and older from the August 2021-August 2023 National Health and Nutrition Examination Survey (NHANES). Trends in the prevalence of high total cholesterol and low HDL-C are also presented.

Methods: Data from the August 2021-August 2023 NHANES were used to estimate the prevalence of high total cholesterol (240 mg/dL or higher) and low HDL-C (less than 40 mg/dL).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!